<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491491</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-07-4466-AN-CTIL</org_study_id>
    <nct_id>NCT00491491</nct_id>
  </id_info>
  <brief_title>Zevalin-beam for Aggressive Lymphoma</brief_title>
  <official_title>SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amsterdam UMC, location VUmc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning&#xD;
      regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation&#xD;
      in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall&#xD;
      and disease-free survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years after transplantation</time_frame>
    <description>actuarial 2 year survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>2 years after transplantation</time_frame>
    <description>actuarial 2-year PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>100 days after transplantation</time_frame>
    <description>complete response (CR) and partial response (PR) proportion at day 100,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic Recovery</measure>
    <time_frame>100 days after transplantation</time_frame>
    <description>time to hematopoietic recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade III Toxicity</measure>
    <time_frame>100 days after transplantation</time_frame>
    <description>incidence of infection, grade III-IV toxicities, treatment-related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Malignancies</measure>
    <time_frame>5 years after transplantation</time_frame>
    <description>incidence of myelodysplastic syndrome (MDS), and secondary acute myelogenous leukemia (AML).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Z-BEAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibritumomab tiuxetan (zevalin) BEAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard BEAM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard BEAM chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibritumomab tiuxetan</intervention_name>
    <description>0.4 mCi/kg</description>
    <arm_group_label>Z-BEAM</arm_group_label>
    <other_name>zevalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BEAM chemotherapy and autologous stem-cell transplantation</intervention_name>
    <arm_group_label>Z-BEAM</arm_group_label>
    <arm_group_label>standard BEAM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with CD20 positive diffuse large B-cell lymphoma as confirmed by a&#xD;
             pathological biopsy report.&#xD;
&#xD;
          2. Patients who are candidates for autologous stem-cell transplantation due to primary&#xD;
             refractory or first relapse of disease.&#xD;
&#xD;
          3. Patients must have chemo-sensitive disease achieving at least partial response (Cheson&#xD;
             2007 criteria) to last chemotherapy.&#xD;
&#xD;
          4. Age ≥ 18 years and age ≤ 70&#xD;
&#xD;
          5. Patients with adequate autologous stem cell collection for transplantation (target ≥&#xD;
             2.5 x 106 CD34+ cells/kg).&#xD;
&#xD;
          6. Patients must sign written informed consent.&#xD;
&#xD;
          7. Adequate birth control in fertile patients.&#xD;
&#xD;
          8. All prior chemotherapy completed at least three weeks before study treatment.&#xD;
&#xD;
          9. Marrow involvement less than 25% at transplantation, no limitation on blood counts&#xD;
             (low platelet count allowed).&#xD;
&#xD;
         10. Negative HIV antibody.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. 1. Chemo-refractory disease as determined by less than partial response (Cheson 2007&#xD;
             Criteria) to last chemotherapy.&#xD;
&#xD;
          2. Two or more relapses after initial response to induction chemotherapy.&#xD;
&#xD;
          3. High-grade transformation from earlier diagnosis of low-grade lymphoma. Patients with&#xD;
             &quot;De Novo&quot; Transformed DLBCL, defined as DLBCL only on lymph node biopsy and a&#xD;
             discordant marrow with para-trabecular small cells at first diagnosis of lymphoma, are&#xD;
             eligible if adherent all other selection criteria.&#xD;
&#xD;
          4. Bilirubin &gt; 3.0 mg/dl, transaminases &gt; 3 times upper normal limit.&#xD;
&#xD;
          5. Creatinine &gt; 2.0 mg/dl.&#xD;
&#xD;
          6. ECOG Performance status &gt; 2.&#xD;
&#xD;
          7. Uncontrolled infection.&#xD;
&#xD;
          8. Pregnancy or lactation.&#xD;
&#xD;
          9. Abnormal lung diffusion capacity (DLCO &lt; 40% predicted).&#xD;
&#xD;
         10. Severe cardiovascular disease; New York Heart Association (NYHA) Functional&#xD;
             Classification ≥2.&#xD;
&#xD;
         11. Active CNS disease involvement.&#xD;
&#xD;
         12. Presence of any other malignancy or history of prior malignancy within 5 years of&#xD;
             study entry. Within 5 years, patients treated for Stage I or II cancers are eligible&#xD;
             provided they have a life expectancy &gt; 5 years in relation to this prior malignance.&#xD;
             The 5-year exclusion rule does not apply to-non melanoma skin tumors and in situ&#xD;
             cervical cancer.&#xD;
&#xD;
         13. Pleural effusion or ascites &gt; 1 liter.&#xD;
&#xD;
         14. Known hypersensitivity to rituximab.&#xD;
&#xD;
         15. Psychiatric conditions/disease that impair the ability to give informed consent or to&#xD;
             adequately co-operate.&#xD;
&#xD;
         16. Prior radioimmunotherapy.&#xD;
&#xD;
         17. Prior autologous or allogeneic HSCT.&#xD;
&#xD;
         18. Active evidence of Hepatitis B or C infection; Hepatitis B surface antigen positive.&#xD;
&#xD;
         19. Patients who have had prior radiation to the lung will be excluded from the study,&#xD;
             although mediastinal irradiation will be permitted if minimal lung is in the treatment&#xD;
             volume.&#xD;
&#xD;
         20. Patients who have received &gt;500cGy radiation to the kidneys will be excluded from the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avichai Shimoni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chaim Sheba Medical Center, Tel Hashomer, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amrita Krishnan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope National Medical Center, Duarte, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georg-August Universität</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <results_first_submitted>August 13, 2020</results_first_submitted>
  <results_first_submitted_qc>August 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2020</results_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Avichai Shimoni MD</investigator_full_name>
    <investigator_title>Dr. Avichai Shimoni</investigator_title>
  </responsible_party>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <keyword>radioimmunotherapy</keyword>
  <keyword>zevalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Z-BEAM</title>
          <description>ibritumomab tiuxetan (zevalin) BEAM&#xD;
ibritumomab tiuxetan: 0.4 mCi/kg&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
        </group>
        <group group_id="P2">
          <title>Standard BEAM</title>
          <description>standard BEAM chemotherapy&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Z-BEAM</title>
          <description>ibritumomab tiuxetan (zevalin) BEAM&#xD;
ibritumomab tiuxetan: 0.4 mCi/kg&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
        </group>
        <group group_id="B2">
          <title>Standard BEAM</title>
          <description>standard BEAM chemotherapy&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="23" upper_limit="66"/>
                    <measurement group_id="B2" value="51" lower_limit="24" upper_limit="67"/>
                    <measurement group_id="B3" value="55" lower_limit="23" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>Study stopped early due to slow accrual</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Israel</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>actuarial 2 year survival</description>
        <time_frame>2 years after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Z-BEAM</title>
            <description>ibritumomab tiuxetan (zevalin) BEAM&#xD;
ibritumomab tiuxetan: 0.4 mCi/kg&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
          <group group_id="O2">
            <title>Standard BEAM</title>
            <description>standard BEAM chemotherapy&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>actuarial 2 year survival</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="79" upper_limit="100"/>
                    <measurement group_id="O2" value="62" lower_limit="39" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>actuarial 2-year PFS</description>
        <time_frame>2 years after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Z-BEAM</title>
            <description>ibritumomab tiuxetan (zevalin) BEAM&#xD;
ibritumomab tiuxetan: 0.4 mCi/kg&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
          <group group_id="O2">
            <title>Standard BEAM</title>
            <description>standard BEAM chemotherapy&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>actuarial 2-year PFS</description>
          <units>percentage of PARTICIPANTS</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="39" upper_limit="80"/>
                    <measurement group_id="O2" value="37" lower_limit="14" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response</title>
        <description>complete response (CR) and partial response (PR) proportion at day 100,</description>
        <time_frame>100 days after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Z-BEAM</title>
            <description>ibritumomab tiuxetan (zevalin) BEAM&#xD;
ibritumomab tiuxetan: 0.4 mCi/kg&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
          <group group_id="O2">
            <title>Standard BEAM</title>
            <description>standard BEAM chemotherapy&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response</title>
          <description>complete response (CR) and partial response (PR) proportion at day 100,</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematopoietic Recovery</title>
        <description>time to hematopoietic recovery</description>
        <time_frame>100 days after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Z-BEAM</title>
            <description>ibritumomab tiuxetan (zevalin) BEAM&#xD;
ibritumomab tiuxetan: 0.4 mCi/kg&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
          <group group_id="O2">
            <title>Standard BEAM</title>
            <description>standard BEAM chemotherapy&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Hematopoietic Recovery</title>
          <description>time to hematopoietic recovery</description>
          <units>DAYS</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7" upper_limit="21"/>
                    <measurement group_id="O2" value="11" lower_limit="10" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade III Toxicity</title>
        <description>incidence of infection, grade III-IV toxicities, treatment-related mortality</description>
        <time_frame>100 days after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Z-BEAM</title>
            <description>ibritumomab tiuxetan (zevalin) BEAM&#xD;
ibritumomab tiuxetan: 0.4 mCi/kg&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
          <group group_id="O2">
            <title>Standard BEAM</title>
            <description>standard BEAM chemotherapy&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Grade III Toxicity</title>
          <description>incidence of infection, grade III-IV toxicities, treatment-related mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>grade III toxicity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>infection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>none</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Malignancies</title>
        <description>incidence of myelodysplastic syndrome (MDS), and secondary acute myelogenous leukemia (AML).</description>
        <time_frame>5 years after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Z-BEAM</title>
            <description>ibritumomab tiuxetan (zevalin) BEAM&#xD;
ibritumomab tiuxetan: 0.4 mCi/kg&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
          <group group_id="O2">
            <title>Standard BEAM</title>
            <description>standard BEAM chemotherapy&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Malignancies</title>
          <description>incidence of myelodysplastic syndrome (MDS), and secondary acute myelogenous leukemia (AML).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Z-BEAM</title>
          <description>ibritumomab tiuxetan (zevalin) BEAM&#xD;
ibritumomab tiuxetan: 0.4 mCi/kg&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
        </group>
        <group group_id="E2">
          <title>Standard BEAM</title>
          <description>standard BEAM chemotherapy&#xD;
BEAM chemotherapy and autologous stem-cell transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>JC virus encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Avichai Shimoni</name_or_title>
      <organization>Chaim Sheba Medical Center</organization>
      <phone>972 3 530 5303</phone>
      <email>ashimoni@sheba.health.gov.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

